Earnings ·
AbbVie cuts full-year adjusted EPS guidance to $13.76-$13.96 after $216M Q3 IPR&D charge
ABBVAbbVie Inc.
AbbVie Inc. updated its financial outlook for 2026, lowering the full-year adjusted diluted earnings per share range to $13.76–$13.96 from a previous high of $14.07. The revision reflects an estimated $216 million in pre-tax acquired in-process research and development (IPR&D) and milestone expenses incurred during the third quarter, which reduced both GAAP and adjusted diluted EPS by $0.11 per share. Consequently, the company also lowered its third-quarter 2026 adjusted diluted EPS guidance to a range of $3.73–$3.77. AbbVie Inc. operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies.